Order Article Reprints

Casili G, Scuderi SA, Lanza M, Filippone A, Mannino D, Giuffrida R, Colarossi C, Mare M, Capra AP, De Gaetano F, et al. Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC). Cancers. 2023; 15(10):2796. https://doi.org/10.3390/cancers15102796

Casili, Giovanna, Sarah Adriana Scuderi, Marika Lanza, Alessia Filippone, Deborah Mannino, Raffaella Giuffrida, Cristina Colarossi, Marzia Mare, Anna Paola Capra, Federica De Gaetano, and et al. 2023. "Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC)" Cancers 15, no. 10: 2796. https://doi.org/10.3390/cancers15102796

Casili, G., Scuderi, S. A., Lanza, M., Filippone, A., Mannino, D., Giuffrida, R., Colarossi, C., Mare, M., Capra, A. P., De Gaetano, F., Portelli, M., Militi, A., Cuzzocrea, S., Paterniti, I., & Esposito, E. (2023). Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC). Cancers, 15(10), 2796. https://doi.org/10.3390/cancers15102796